| Name | Diurnal Group |
|---|---|
| Epic | DNL |
| Isin | GB00BDB6Q760 |
| Industry | Pharmaceuticals & Biotechnology |
| Latest share price | 27.30p | Net gearing | n/a |
|---|---|---|---|
| Market capitalisation | £46.33 | Debt ratio | n/a |
| Shares in issue | 169.72 | Debt-to-equity ratio | n/a |
| P/E ratio | n/a | Assets / equity ratio | n/a |
| Total dividends per share | n/a | Price to book value | n/a |
| Dividend yield | n/a | ROCE | -30.96 |
| Dividend cover | n/a | EPS growth | n/a |
| Earning per share | -7.3 | 52-week high / low | 9.75p / 66.50p |
| Type | Ex-date | Pay-date | Net-dividend |
|---|---|---|---|
| No dividends declared | |||
| Company name | Diurnal Group |
|---|---|
| Address | Cardiff Medicentre, Heath Park, Cardiff,, United Kingdom, CF14 4UJ |
| Telephone | +44 (0)29 2068 2069 |
| Website | http://www.diurnal.co.uk |
| Director | Position |
|---|---|
| Mr Alan Raymond | Non-Executive Director |
| Dr Sam Williams | Non-Executive Director |
| Mr Anders Härfstrand | Non-Executive Chairman |
| Mr John Goddard | Senior Independent Director |
| Mr Deborah Jorn | Independent Non-Executive Director |
| Mr Jean-Michel Cosséry | Independent Non-Executive Director |
| Mr Richard Ross | Chief Scientific Officer |
| Mr Richard Bungay | Interim CEO |
| Assets £ (m) | 2021 | 2020 | 2019 |
|---|---|---|---|
| Reporting date | 30/06/21 | 30/06/20 | 30/06/19 |
| Intangible asssets and goodwill | 0.09 | 0.08 | 0.05 |
| Investments and other non-current assets | n/a | 1.67 | n/a |
| Total non-current assets | 0.24 | 1.77 | 0.08 |
| Inventory / work in progress | 1.62 | 1.24 | 0.67 |
| Trade and other receivables | 4.92 | 2.53 | 3.56 |
| Cash and equivalents | 34.04 | 15.43 | 9.15 |
| Other current assets and asset held for resale | n/a | n/a | n/a |
| Total of all assets | 41.79 | 20.98 | 13.46 |
| Liabilities £ (m) | 2021 | 2020 | 2019 |
|---|---|---|---|
| Short term liabilities | 4.16 | 2.56 | 2.5 |
| Long term liabilities | 0.06 | 0.04 | 0.02 |
| Other liabilites / pension etc | n/a | n/a | n/a |
| Total of all liabilities | 4.23 | 2.59 | 2.52 |
| Net assets £ (m) | 2021 | 2020 | 2019 |
|---|---|---|---|
| Net assets | 37.56 | 18.39 | 10.94 |
| Equity £ (m) | 2021 | 2020 | 2019 |
|---|---|---|---|
| Share capital | 8.4 | 6.08 | 4.23 |
| Minority interests | n/a | n/a | n/a |
| Retained earnings | -45.3 | -35.72 | -32.49 |
| Share premium account | 77.41 | 50.97 | 42.15 |
| Total equity | 37.56 | 18.39 | 10.94 |
| Income £ (m) | 2021 | 2020 | 2019 |
|---|---|---|---|
| Turnover | n/a | n/a | n/a |
| Operating profit | -11.6 | -5.39 | -14.53 |
| Pre-tax profit | -11.54 | -5.28 | -14.4 |